3174

CSOP China Healthcare Disruption ETF

Solactive China Health Disrupt NR HKD

NAV as of 22-Sep-2023

2.4567

4 Week: 2.40 - 2.58

52 Week: 2.39 - 3.92

Latest Closing Price

2.47

Premium / Discount

0.94

Expense Ratio

0.99%

Investment Objective

The investment objective of the Sub-Fund is to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Index, namely, Solactive China Healthcare Disruption Index (the “Index”). There is no assurance that the Sub-Fund will achieve its investment objective.

Main Fund Characteristics

Fund Manager:
CSOP Asset Management Limited
Asset Under Management:
25,950,391
Launch Date:
N.A
Asset Class:
Equity
Replication Method:
Physical-Sample
Number of Holdings:
36
Trading Currency:
HKD
Style:
Large Growth
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
HKEX

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-28.931.97-14.70
1 Day2.580.000.00
1 Week-1.525.01-0.30
1 Month1.998.630.23
3 Months-5.8116.01-0.36
6 Months-22.2121.15-1.05
1 Year-6.0937.04-0.16
2 Years-62.1559.33-1.05
3 Years0.000.000.00
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2013201420152016201720182019202020212022
Price (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.0000-27.3472
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.00000.00000.000088.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
N.A

Portfolio Data

Total Number of Holdings: 36

Number of Bond Holdings: 0

Number of Equity Holdings: 35

Total Market Value: 25,950,391

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1WuXi Biologics (Cayman) Inc8.434251,31802,188,713
2Wuxi AppTec Co Ltd8.316425,27102,158,143
3JD Health International Inc7.184744,76501,864,462
4Shanghai Fosun Pharmaceutical (Group) Co Ltd Class6.036185,68901,566,395
5CSPC Pharmaceutical Group Ltd5.6488253,61301,465,883
6Alibaba Health Information Technology Ltd5.2318289,48401,357,680
7Hansoh Pharmaceutical Group Co Ltd4.8344126,08501,254,546
8Innovent Biologics Inc4.723432,73001,225,738
9Sino Biopharmaceutical Ltd4.5563402,16701,182,371
10Genscript Biotech Corp Class H3.461945,5110898,387

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant16.75
Large59.25
Medium20.23
Small3.46
Micro0.00

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

19.5964

Price/Book*

2.1342

Price/Sales*

2.4859

Price/Cash Flow*

16.2141

Dividend Yield*

1.3347

Growth Measures

Long-Term Earnings

13.1686

Historical Earnings

2.9160

Sales Growth

14.5289

Cash-Flow Growth

4.5301

Book-Value Growth

10.7072

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you